TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
ErGe BioTech AB
Closing information (x1000 EUR)
| Closing information | 2024/04 | 2023/04 | 2022/04 |
| Turnover |
112
|
126
|
127 |
| Financial expenses |
0
|
0
|
0 |
| Earnings before taxes |
22
|
45
|
44 |
| EBITDA |
22
|
45
|
44 |
| Total assets |
171
|
162
|
145 |
| Current assets |
83
|
71
|
45 |
| Current liabilities |
5
|
15
|
22 |
| Equity capital |
158
|
136
|
111 |
| - share capital |
4
|
4
|
5 |
| Employees (average) |
1
|
1
|
2 |
Financial ratios
| Fiscal year | 2024/04 | 2023/04 | 2022/04 |
| Solvency |
92.4%
|
84.0%
|
76.6% |
| Turnover per employee |
112
|
126
|
64 |
| Profit as a percentage of turnover |
19.6%
|
35.7%
|
34.6% |
| Return on assets (ROA) |
12.9%
|
27.8%
|
30.3% |
| Current ratio |
1660.0%
|
473.3%
|
204.5% |
| Return on equity (ROE) |
13.9%
|
33.1%
|
39.6% |
| Change turnover |
-9
|
11
|
-4 |
| Change turnover % |
-8%
|
9%
|
-3% |
| Chg. No. of employees |
0
|
-1
|
0 |
| Chg. No. of employees % |
0%
|
-50%
|
0% |
Total value of public sale
| Fiscal year | 2024/04 | 2023/04 | 2022/04 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.